A Trial to Evaluate Para-aortic Lymphadenectomy for Gastric Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Radical gastrectomy with regional lymphadenectomy is the only curative treatment option for gastric cancer. The extent of lymphadenectomy, however, is controversial. The two European randomized trials only reported an increase in operative morbidity and mortality, but failed to show survival benefit, in the D2 lymphadenectomy group. We conducted a randomized controlled trial to compare the Japanese standard D2 and D2 + para-aortic nodal dissection.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
up to 75 Years (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
histologically proven adenocarcinoma
75 years old or younger
forced expiratory volume in one second ≥ 50 %
arterial oxygen pressure in room air ≥ 70 mmHg
creatinine clearance ≥ 50 ml/min
written consent. Intraoperatively
Macroscopic T staging is T2-subserosa, T3, or T4
potentially curative operation is possible
no gross metastasis in para-aortic nodes (frozen section diagnosis not allowed)
peritoneal lavage cytology is negative for cancer cells
Carcinoma in the remnant stomach
Borrmann type 4 (linitis plastica)
synchronous or metachronous malignancy in other organs except for cervical carcinoma in situ and colorectal focal cancer in adenoma
past history of myocardial infarction or positive results of exercise ECG
liver cirrhosis, or chronic liver disease with indocyanine green test ≥10%